Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stake Cut by Stonepine Capital Management LLC

Stonepine Capital Management LLC reduced its stake in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) by 14.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 597,700 shares of the company's stock after selling 102,300 shares during the quarter. Zevra Therapeutics comprises about 4.0% of Stonepine Capital Management LLC's portfolio, making the stock its 5th biggest position. Stonepine Capital Management LLC owned 1.12% of Zevra Therapeutics worth $4,985,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also modified their holdings of the stock. Barclays PLC raised its holdings in shares of Zevra Therapeutics by 292.6% during the third quarter. Barclays PLC now owns 57,599 shares of the company's stock worth $399,000 after acquiring an additional 42,926 shares during the period. Price T Rowe Associates Inc. MD grew its position in shares of Zevra Therapeutics by 51.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 20,565 shares of the company's stock valued at $172,000 after acquiring an additional 6,966 shares during the period. JPMorgan Chase & Co. grew its position in shares of Zevra Therapeutics by 50.5% in the 4th quarter. JPMorgan Chase & Co. now owns 27,490 shares of the company's stock valued at $229,000 after acquiring an additional 9,225 shares during the period. Raymond James Financial Inc. bought a new position in shares of Zevra Therapeutics in the 4th quarter valued at about $224,000. Finally, Wells Fargo & Company MN grew its position in shares of Zevra Therapeutics by 65.4% in the 4th quarter. Wells Fargo & Company MN now owns 29,701 shares of the company's stock valued at $248,000 after acquiring an additional 11,744 shares during the period. 35.03% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, Director John B. Bode bought 10,000 shares of the business's stock in a transaction that occurred on Wednesday, March 19th. The shares were acquired at an average cost of $7.96 per share, with a total value of $79,600.00. Following the completion of the purchase, the director now directly owns 40,000 shares in the company, valued at $318,400. The trade was a 33.33% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 2.40% of the stock is owned by insiders.

Zevra Therapeutics Price Performance

ZVRA stock traded up $0.05 during trading on Wednesday, reaching $8.66. 552,745 shares of the company were exchanged, compared to its average volume of 641,323. The company has a 50-day moving average of $7.58 and a two-hundred day moving average of $8.09. The company has a market capitalization of $473.53 million, a price-to-earnings ratio of -4.40 and a beta of 1.87. Zevra Therapeutics, Inc. has a twelve month low of $4.20 and a twelve month high of $9.76. The company has a debt-to-equity ratio of 0.84, a current ratio of 2.88 and a quick ratio of 2.88.

Zevra Therapeutics (NASDAQ:ZVRA - Get Free Report) last announced its quarterly earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.15. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. The firm had revenue of $20.40 million during the quarter, compared to analysts' expectations of $16.96 million. During the same period in the prior year, the company posted ($0.40) EPS. As a group, equities analysts predict that Zevra Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently issued reports on ZVRA. JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $25.00 price objective on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. Citigroup reiterated an "outperform" rating on shares of Zevra Therapeutics in a research note on Wednesday, May 14th. HC Wainwright reaffirmed a "buy" rating and set a $20.00 price objective on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Finally, Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, March 13th. Eight research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $22.29.

Zevra Therapeutics Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.